Study SC-101 in Subjects With Advanced Malignancies

Official title

A Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-101 in Subjects With Advanced or Metastatic Solid Tumors That Express Nectin-4

Overview

This study will evaluate the safety, pharmacokinetics, and anti-cancer efficacy of SC-101 in subjects with advanced or metastatic solid tumors.

Detailed description

This study is the first-in-human (FIH), multi-center, open-label trial of SC-101, including the dose escalation and expansion phases.

The dose escalation study is primarily designed to assess the safety and tolerability of SC-101 and to determine the recommended dose(s) for the dose expansion study. The dose expansion study is designed with the primary objective of evaluating the clinical activity of SC-101 in patients with metastatic urothelial carcinoma or other solid tumors that express Nectin-4.

Interventions

• Drug SC-101
  All subjects will receive a single intravenous (IV) infusion of SC-101 once weekly.

Primary outcome measures

• Incidence of adverse events (dose escalation phase) [Time frame: Up to 30 days after the last dose of study drug]
• Objective response rate (dose expansion phase) [Time frame: Every 8 weeks (± 7 days)]

Secondary outcome measures (7)

• Maximum plasma concentration (Cmax) of SC-101 and monomethyl auristatin E (MMAE) when given as monotherapy [Time frame: From Cycle 1 Day 1 through end of treatment (EOT)]
• Minimum plasma concentration (Cmin) of SC-101 and monomethyl auristatin E (MMAE) when given as monotherapy [Time frame: From Cycle 1 Day 1 through end of treatment (EOT)]
• Area under the plasma concentration-time curve (AUC) of SC-101 and monomethyl auristatin E (MMAE) when given as monotherapy [Time frame: From Cycle 1 Day 1 through end of treatment (EOT)]
• Elimination half-life (t1/2) of SC-101 and monomethyl auristatin E (MMAE) when given as monotherapy [Time frame: From Cycle 1 Day 1 through end of treatment (EOT)]
• Number of participants positive for anti-drug antibodies (ADA) [Time frame: From Cycle 1 Day 1 through end of treatment (EOT)]
• Duration of Response (DoR) [Time frame: Every 8 weeks (± 7 days)]
• Disease Control Rate (DCR) [Time frame: Every 8 weeks (± 7 days)]

Eligibility criteria

Inclusion criteria

• Subjects voluntarily agree to participate in the study and sign the Informed Consent Form (ICF).
• 18 to 80 years of age at the time of signature of the ICF, without gender limitation.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Life expectancy of ≥ 3 months as assessed by the investigator.
• Women and men of childbearing potential must be advised and agree to practice effective methods of contraception during the study.
• Understand study requirements, and willing and able to comply with arrangements of study and follow-up procedures.
• Adequate Bone Marrow Reserve and Organ Functions.
• Subjects must have measurable disease according to RECIST (version 1.1).
• Histologically or cytologically confirmed advanced malignant solid tumors.
• For non-urothelial carcinoma patients enrolled in the dose expansion study: Subjects must have a positive expression of Nectin-4 in their tumor samples as confirmed by the central laboratory.
• Subjects are willing to follow study procedures.

Exclusion criteria

• History of other malignancy(ies) within 3 years before signing the ICF, except for non-melanoma skin cancer, cervical carcinoma in situ, or other malignant tumors that are considered to have been cured.
• Any anticancer therapy, including any investigational drug, within 2 weeks before the first dose of the study drug.
• Uncontrolled central nervous system metastases.
• Prior treatment with Nectin-4-targeting anti-cancer therapy.
• Preexisting treatment-related toxicity Grade ≥ 2 (except alopecia).
• Preexisting Grade ≥ 2 (as per CTCAE v5.0) sensory or motor neuropathy.
• Major surgery within 4 weeks prior to the first dose of the study drug.
• History of interstitial lung disease (ILD), preexisting ILD, or the suspected ILD that cannot be ruled out by imaging examination at screening.
• Preexisting active keratitis or corneal ulcerations.
• Preexisting serious dermatological diseases, or having experienced serious skin toxicities during the prior anti-cancer treatment (e.g., Stevens-Johnson syndrome, toxic Epidermal Necrolysis, etc.).
• Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of study drug, or fever within 14 days prior to the first dose of the study drug.
• History of uncontrolled diabetes mellitus.
• History of thromboembolic events and bleeding disorders ≤ 6 months (e.g.,deep vein thrombosis (DVT) or pulmonary embolism ( PE)) prior to the first dose of the study drug.
• Positive results of virus serology tests.
• History of serious cardiovascular and cerebrovascular diseases, including but not limited to:

• Serious cardiac arrhythmias or conduction abnormalities, such as ventricular arrhythmia require treatment, and grade 2 or 3 atrioventricular block.
• QTc prolongation to >450 milliseconds (ms) in males and >470 ms in females based on ECG.
• Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or transient ischemic attack (TIA) within 6 months prior to the first dose of the study drug.
• New myocardial infarction or unstable angina within 6 months before the first dose of the study drug.
• Uncontrolled hypertension.
• Require ongoing therapy with a medication that is a strong inhibitor or inducer of the cytochrome P450 3A4 (CYP3A4) enzymes.
• Known sensitivity to any of the ingredients of the investigational product.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 5 centers

• Beijing Cancer Hospital — Beijing
• Hunan Cancer Hospital — Changsha
• Nanjing Drum Tower Hospital — Nanjing
• Fudan University Shanghai Cancer Center — Shanghai
• Tianjin Medical University Cancer Institute and Hospital — Tianjin

Identifiers

NCT: NCT06220838 · SC-101-101

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗